Not a good buy right now: price is in a clear downtrend (SMA_200 > SMA_20 > SMA_5) and momentum remains bearish despite being oversold.
Intellectia signals do not support an immediate entry (no AI Stock Picker / no SwingMax), so there’s no high-conviction timing edge for an impatient buyer.
Oversold RSI (~17.8) can trigger short bounces, but with weak trend structure and small-cap fragility, the risk/reward is unfavorable for an immediate buy.
Near-term catalyst risk is elevated into earnings (2026-02-19 after hours) and the stock has recently sold off hard (-6.14% regular session).
Technical Analysis
Trend: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling a persistent downtrend.
Momentum: MACD histogram is negative (-0.711) and only “negatively contracting,” which suggests downside momentum is easing but not reversed.
Condition: RSI_6 at 17.818 = deeply oversold (bounce potential), but oversold alone is not a buy trigger without reversal confirmation.
Levels: Current price (~7.035) is below S1 (7.131), indicating a breakdown.
Next supports: S2 ~6.244 (key downside level).
Overhead pivot/resistance: Pivot 8.567, then R1 10.003.
Pattern-based odds (provided): modest upside bias next day/week (+1.55% / +2.09%), but negative over next month (-2.45%), aligning with the larger bearish trend.
Net income: -$2,983,006, improved +11.07% YoY (loss narrowed, still negative).
EPS: -3.49, down -50.50% YoY (per-share performance worsened despite net loss improvement; likely dilution/other factors implied by the data).
Gross margin: 19.33, +263.35% YoY (material margin improvement, but still not high enough to offset operating losses yet).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so the recent trend in Wall Street ratings/targets cannot be confirmed.
Practical read-through from available data: the bull case hinges on FDA/clinical milestones and U.S. market expansion; the bear case is ongoing losses + broken technical trend with no third-party rating support shown.
Wall Street analysts forecast INBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast INBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INBS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
